The results indicated that MP-A enhanced the production of SCFAs in the gut while inhibiting the expression and activity of PPARγ and SREBP-1c, thereby counteracting HFD-induced NAFLD. Here, SREBF1 is linked to metabolic dysfunction-associated steatotic liver disease.